Current status of treatment for primary effusion lymphoma

Intractable and Rare Diseases Research

Volumn 3, Issue 3, 2014, Pages 65-74

  Seiji, Okada ^a   Hiroki, Goto ^a   Mihoko, Yotsumoto ^b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

combination antiretroviral therapy (cART); HIV 1 AIDS; Human herpes virus 8 Kaposi sarcoma associated herpes virus (HHV 8 KSHV); NF B; PEL xenograft mouse model; Primary effusion lymphoma (PEL)

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ALPHA INTERFERON; BERBERINE; BEVACIZUMAB; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CEPHARANTHINE; CIDOFOVIR; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DAPSONE; DIETHYLDITHIOCARBAMIC ACID; DOXORUBICIN; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENALIDOMIDE; METHOTREXATE; PENTAMIDINE; PREDNISONE; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RALTEGRAVIR; RITUXIMAB; UNINDEXED DRUG; VINCRISTINE; ZIDOVUDINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANGIOGENESIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DNA VIRUS INFECTION; DRUG CONJUGATION; DRUG EFFICACY; DRUG MEGADOSE; ENZYME ACTIVATION; EPSTEIN BARR VIRUS INFECTION; GENE PRODUCT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; KAPOSI SARCOMA; KIDNEY METASTASIS; LARGE CELL LYMPHOMA; LYMPHOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PATHOGENESIS; PLASMABLASTIC LYMPHOMA; PNEUMOCYSTIS PNEUMONIA; PRIMARY EFFUSION LYMPHOMA; PROSPECTIVE STUDY; PYOTHORAX ASSOCIATED LYMPHOMA; REVIEW; VIRUS REPLICATION;

EID: 85010162747     PISSN: 21863644     EISSN: 2186361x     Source Type: Journal    
DOI: 10.5582/irdr.2014.01010     Document Type: Article

References (84)

1. Said J, Cesarman, E. Primary effusion lymphoma. In:Steven H. Swerdlow E, M.D. Campo, Nancy Lee, M.D. Harris, Elaine S., M.D. Jaffe, editor. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition. Lyon: International Agency for Research on Cancer, 2008: 260-261.
2. Pan ZG, Zhang QY, Lu ZB, Quinto T, Rozenvald IB, Liu LT, Wilson D, Reddy V, Huang Q, Wang HY, Ren YS. Extracavitary KSHV-associated large B-Cell lymphoma:A distinct entity or a subtype of primary effusion lymphoma? Study of 9 cases and review of an additional 43 cases. Am J Surg Pathol. 2012; 36:1129-1140.
3. Knowles DM, Inghirami G, Ubriaco A, Dalla-Favera R. Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the possible pathogenetic role of the Epstein-Barr virus. Blood. 1989; 73:792-799.
4. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995; 332:1186-1191.
5. Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, Knowles DM. Primary effusion lymphoma: A distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood. 1996; 88:645-656.
6. Riva G, Luppi M, Barozzi P, Forghieri F, Potenza L. How I treat HHV8/KSHV-related diseases in posttransplant patients. Blood. 2012; 120:4150-4159.
7. Song JY, Jaffe ES. HHV-8-positive but EBV-negative primary effusion lymphoma. Blood. 2013; 122:3712.
8. Shi Y, Hou Y, Hu Q, Su J, Zeng H, Tan Y. A rare case of HHV-8-positive/HIV-negative/EBV-negative primary effusion lymphoma in a renal transplant recipient. Cytopathology. 2012; 23:137-139.
9. Mettler TN, Cioc AM, Singleton TP, McKenna RW, Pambuccian SE. Pleural primary effusion lymphoma in an elderly patient. Diagn Cytopathol. 2012; 40:903-905.
10. Beral V, Peterman T, Berkelman R, Jaffe H. AIDS associated non-Hodgkin lymphoma. Lancet. 1991; 337:805-809.
11. Simonelli C, Spina M, Cinelli R, Talamini R, Tedeschi R, Gloghini A, Vaccher E, Carbone A, Tirelli U. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: A single-institution study. J Clin Oncol. 2003; 21:3948-3954.
12. Ota Y, Hishima T, Mochizuki M, et al. Classification of AIDS-related lymphoma cases between 1987 and 2012 in Japan based on the WHO classification of lymphomas, fourth edition. Cancer Med. 2014; 3:143-153.
13. Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF. HIV-associated lymphomas and gammaherpesviruses. Blood. 2009; 113: 1213-1224.
14. Chen YB, Rahemtullah A, Hochberg E. Primary effusion lymphoma. Oncologist. 2007; 12:569-576.
15. Castillo JJ, Shum H, Lahijani M, Winer ES, Butera JN. Prognosis in primary effusion lymphoma is associated with the number of body cavities involved. Leuk Lymphoma. 2012; 53:2378-2382.
16. Ansari MQ, Dawson DB, Nador R, Rutherford C, Schneider NR, Latimer MJ, Picker L, Knowles DM, McKenna RW. Primary body cavity-based AIDS-related lymphomas. Am J Clin Pathol. 1996; 105:221-229.
17. Jones D, Ballestas ME, Kaye KM, Gulizia JM, Winters GL, Fletcher J, Scadden DT, Aster JC. Primary-effusion lymphoma and Kaposi's sarcoma in a cardiac-transplant recipient. N Engl J Med. 1998; 339:444-449.
18. Klepfish A, Sarid R, Shtalrid M, Shvidel L, Berrebi A, Schattner A. Primary effusion lymphoma (PEL) in HIV-negative patients-a distinct clinical entity. LeukLymphoma. 2001; 41:439-443.
19. Chadburn A, Hyjek E, Mathew S, Cesarman E, Said J, Knowles DM. KSHV-positive solid lymphoma srepresent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol. 2004; 28:1401-1416.
20. Boulanger E, Meignin V, Oksenhendler E. Bortezomib(PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma. Br J Haematol. 2008;141:559-561.
21. Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma. Blood. 2012; 119:3245-3255.
22. Jenner RG, Maillard K, Cattini N, Weiss RA, Boshoff C, Wooster R, Kellam P. Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc Natl Acad Sci USA. 2003; 100:10399-10404.
23. Pan L, Milligan L, Michaeli J, Cesarman E, Knowles DM. Polymerase chain reaction detection of Kaposi's sarcoma associated herpesvirus-optimized protocols and their application to myeloma. J Mol Diagn. 2001; 3:32-38.
24. Simonelli C, Tedeschi R, Gloghini A, Bortolin MT, Spina M, Bidoli E, Cinelli R, De Paoli P, Carbone A, Tirelli U. Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy. Clin Infect Dis. 2005; 40:1022-1027.
25. Cesarman E. Gammaherpes virus and lymphoproliferative disorders in immuno compromised patients. Cancer Lett. 2011; 305:163-174.
26. Drexler HG, Meyer C, Gaidano G, Carbone A. Constitutive cytokine production by primary effusion (body cavity-based) lymphoma-derived cell lines. Leukemia. 1999; 13:634-640.
27. Michai M, Goto H, Hattori S, Vaeteewoottacharn K,
28. Wongkham C, Wongkham S, Okada S. Soluble CD30: A possible serum tumor marker for primary effusion lymphoma. Asian Pac J Cancer Prev. 2012; 13:4939-4941.
29. Tedeschi R, Enbom M, Bidoli E, Linde A, De Paoli P, Dillner J. Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. J Clin Microbiol. 2001; 39:4269-4273.
30. Friborg J, Jr., Kong W, Hottiger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature. 1999; 402:889-894.
31. Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med. 2000; 6:1121-1127.
32. Swanton C, Mann DJ, Fleckenstein B, Neipel F, Peters G, Jones N. Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature. 1997; 390:184-187.
33. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, Mattmann C, Burns K, Bodmer JL, Schroter M, Scaffidi C, Krammer PH, Peter ME, Tschopp J. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature. 1997; 386:517-521.
34. Matta H, Chaudhary PM. Activation of alternative NF-êB pathway by human herpes virus 8-encoded Fasassociated death domain-like IL-1 beta-converting enzyme inhibitory protein (vFLIP). Proc Natl Acad Sci USA. 2004; 101:9399-9404.
35. Kliche S, Nagel W, Kremmer E, Atzler C, Ege A, Knorr T, Koszinowski U, Kolanus W, Haas J. Signaling by human herpesvirus 8 kaposin A through direct membrane recruitment of cytohesin-1. Mol Cell. 2001; 7:833-843.
36. McCormick C, Ganem D. The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science. 2005; 307:739-741.
37. Molden J, Chang Y, You Y, Moore PS, Goldsmith MA. A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem. 1997; 272:19625-19631.
38. Munoz-Fontela C, Marcos-Villar L, Hernandez F, Gallego P, Rodriguez E, Arroyo J, Gao SJ, Avila J, Rivas C. Induction of paclitaxel resistance by the Kaposi's sarcoma-associated herpesvirus latent protein LANA2. J Virol. 2008; 82:1518-1525.
39. Gao SJ, Boshoff C, Jayachandra S, Weiss RA, Chang Y, Moore PS. KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene. 1997; 15:1979-1985.
40. Gottwein E, Mukherjee N, Sachse C, Frenzel C, Majoros WH, Chi JT, Braich R, Manoharan M, Soutschek J, Ohler U, Cullen B.R. A viral micro RNA functions as an orthologue of cellular miR-155. Nature. 2007; 450:1096-1099.
41. Skalsky RL, Samols MA, Plaisance KB, Boss IW, Riva A, Lopez MC, Baker HV, Renne R. Kaposi's sarcoma associated herpes virus encodes an ortholog of miR-155. J Virol. 2007; 81:12836-12845.
42. Wu W, Youm W, Rezk SA, Zhao X. Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma: Report of a rare case and review of 54 cases in the literature. Am J Clin Pathol. 2013; 140:258-273.
43. Alexanian S, Said J, Lones M, Pullarkat ST. KSHV/HHV8-negative effusion-based lymphoma, a distinct entity associated with fluid overload states. Am J Surg Pathol. 2013; 37:241-249.
44. Nakatsuka S, Yao M, Hoshida Y, Yamamoto S, Iuchi K, Aozasa K. Pyothorax-associated lymphoma: A review of 106 cases. J Clin Oncol. 2002; 20:4255-4260.
45. Aozasa K, Takakuwa T, Nakatsuka S. Pyothorax associated lymphoma: A lymphoma developing in chronic inflammation. Adv Anat Pathol. 2005; 12:324-331.
46. Chan AC, Chan JK, Yan KW, Kwong YL. Anaplastic large cell lymphoma presenting as a pleural effusion and mimicking primary effusion lymphoma. A report of 2 cases. Acta Cytol. 2003; 47:809-816.
47. Boulanger E, Gerard L, Gabarre J, Molina JM, Rapp C, Abino JF, Cadranel J, Chevret S, Oksenhendler E. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol. 2005; 23:4372-4380.
48. Lim ST, Rubin N, Said J, Levine AM. Primary effusion lymphoma: Successful treatment with highly active antiretroviral therapy and rituximab. Ann Hematol 2005; 84:551-552.
49. Carbone A, Gloghini A. KSHV/HHV8-associated lymphomas. Br J Haematol. 2008; 140:13-24.
50. Re A, Cattaneo C, Michieli M, et al. High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol. 2003; 21:4423-4427.
51. Bayraktar UD, Ramos JC, Petrich A, Gupta N, Lensing S, Moore PC, Reid EG, Aboulafia DM, Ratner L, Mitsuyasu R, Cooley T, Henry DH, Barr P, Noy A. Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium. Leuk Lymphoma. 2012; 53:2383-2389.
52. Waddington TW, Aboulafia DM. Failure to eradicate AIDS-associated primary effusion lymphoma with highdose chemotherapy and autologous stem cell reinfusion: Case report and literature review. AIDS Patient Care STDS. 2004; 18:67-73.
53. Won JH, Han SH, Bae SB, Kim CK, Lee NS, Lee KT, Park SK, Hong DS, Lee DW, Park HS. Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus. Int J Hematol. 2006; 83:328-330.
54. Bryant A, Milliken S. Successful reduced-intensity conditioning allogeneic HSCT for HIV-related primary effusion lymphoma. Biol Blood Marrow Transplant. 2008; 14:601-602.
55. Weiss R, Mitrou P, Arasteh K, Schuermann D, Hentrich M, Duehrsen U, Sudeck H, Schmidt-Wolf IG, Anagnostopoulos I, Huhn D. Acquired immunodeficiency syndrome-related lymphoma: Simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival-results of the German Multicenter Trial. Cancer. 2006; 106:1560-1568.
56. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: Significant differences in survival with standard chemotherapy. J Clin Oncol. 2005; 23:4430-4438.
57. Oksenhendler E, Clauvel JP, Jouveshomme S, Davi F, Mansour G. Complete remission of a primary effusion lymphoma with antiretroviral therapy. Am J Hematol. 1998; 57:266.
58. Hocqueloux L, Agbalika F, Oksenhendler E, Molina JM. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS. 2001; 15:280-282.
59. Ripamonti D, Marini B, Rambaldi A, Suter F. Treatment of primary effusion lymphoma with highly active antiviral therapy in the setting of HIV infection. AIDS. 2008; 22:1236-1237.
60. Bower M, McCall-Peat N, Ryan N, Davies L, Young AM, Gupta S, Nelson M, Gazzard B, Stebbing J. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood. 2004; 104:2943-2946.
61. Torres HA, Mulanovich V. Management of HIV Infection in Patients With Cancer Receiving Chemotherapy. Clin Infect Dis. 2014. [Epub ahead of print]
62. An J, Sun Y, Fisher M, Rettig MB. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia. 2004; 18:1699-1704.
63. Sarosiek KA, Cavallin LE, Bhatt S, Toomey NL, Natkunam Y, Blasini W, Gentles AJ, Ramos JC, Mesri EA, Lossos IS. Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. Proc Natl Acad Sci USA. 2010; 107:13069-13074.
64. Siddiqi T, Joyce RM. A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab. Clin Lymphoma Myeloma. 2008; 8:300-304.
65. Antar A, El Hajj H, Jabbour M, Khalifeh I, El-Merhi F, Mahfouz R, Bazarbachi A. Primary effusion lymphoma in an elderly patient effectively treated by lenalidomide: Case report and review of literature. Blood Cancer J. 2014; 4: 190.
66. Luppi M, Trovato R, Barozzi P, Vallisa D, Rossi G, Re A, Ravazzini L, Potenza L, Riva G, Morselli M, Longo G, Cavanna L, Roncaglia R, Torelli G. Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia. 2005; 19:473-476.
67. Halfdanarson TR, Markovic SN, Kalokhe U, Luppi M. A non-chemotherapy treatment of a primary effusion lymphoma: Durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. Ann Oncol. 2006; 17:1849-1850.
68. Shiraishi Y, Gotoh K, Towata T, Shimasaki T, Suzu S, Kojima A, Okada S. Therapeutic effects of gammairradiation in a primary effusion lymphoma mouse model. Exp Ther Med. 2010; 1:79-84.
69. Cassoni A, Ali U, Cave J, Edwards SG, Ramsay A, Miller RF, Lee SM. Remission after radiotherapy for a patient with chemotherapy-refractory HIV-associated primary effusion lymphoma. J Clin Oncol. 2008; 26:5297-5299.
70. Takahashi-Makise N, Suzu S, Hiyoshi M, Ohsugi T, Katano H, Umezawa K, Okada S. Biscoclaurine alkaloid cepharanthine inhibits the growth of primary effusion lymphoma in vitro and in vivo and induces apoptosis via suppression of the NF-kappaB pathway. Int J Cancer. 2009; 125:1464-1472.
71. Matsuno T, Kariya R, Yano S, Morino-Koga S, Taura M, Suico MA, Shimauchi Y, Matsuyama S, Okamoto Y, Shuto T, Kai H, Okada S. Diethyldithiocarbamate induces apoptosis in HHV-8-infected primary effusion lymphoma cells via inhibition of the NF-êB pathway. Int J Oncol. 2012; 40:1071-1078.
72. Goto H, Kariya R, Shimamoto M, Kudo E, Taura M, Katano H, Okada S. Antitumor effect of berberine against primary effusion lymphoma via inhibition of NF-êB pathway. Cancer Sci. 2012; 103:775-781.
73. Gopalakrishnan R, Matta H, Chaudhary PM. A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV-associated Primary Effusion Lymphoma and blocks vFLIP K13-induced NF-kappaB. Clin Cancer Res. 2013; 19:5016-5026.
74. Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R, Melnick A, Cerchietti L, Chiosis G, Wang YL, Cesarman E. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood. 2013; 122:2837-2847.
75. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood. 2003 101:1535-1542.
76. Uddin S, Hussain AR, Al-Hussein KA, Manogaran PS, Wickrema A, Gutierrez MI, Bhatia KG. Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells. Clin Cancer Res. 2005; 11:3102-3108.
77. Sin SH, Roy D, Wang L, Staudt MR, Fakhari FD, Patel DD, Henry D, Harrington WJ Jr, Damania BA, Dittmer DP. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood. 2007; 109:2165-2173.
78. Goto H, Okada S. New approaches to treating primary effusion lymphoma. Expert Opinion on Orphan Drugs. 2013; 1:1019-1029.
79. Toomey NL, Deyev VV, Wood C, Boise LH, Scott D, Liu LH, Cabral L, Podack ER, Barber GN, Harrington WJ Jr. Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma. Oncogene. 2001; 20:7029-7040.
80. Wu W, Rochford R, Toomey L, Harrington W Jr, Feuer G. Inhibition of HHV-8/KSHV infected primary effusion lymphomas in NOD/SCID mice by azidothymidine and interferon-alpha. Leuk Res. 2005; 29:545-555.
81. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003; 102:1458-1465.
82. Bhatt S, Ashlock BM, Natkunam Y, Sujoy V, Chapman JR, Ramos JC, Mesri EA, Lossos IS. CD30 targeting with brentuximab vedotin: A novel therapeutic approach to primary effusion lymphoma. Blood. 2013; 122:1233-1242.
83. Aoki Y, Tosato G. Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas. Blood. 1999; 94:4247-4254.
84. Shih T, Lindley C. Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006; 28:1779-1802